NASDAQ ENGN traded up $0.03 on Thursday, hitting $5.96. 57,410 shares of the stock were exchanged, compared to its average volume of 118,128. The company has a market capitalization of $263.53 million, a PE ratio of -3.66 and a beta of -0.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. The business's fifty day moving average is $8.18 and its 200 day moving average is $7.82. enGene has a 52 week low of $4.42 and a 52 week high of $18.40.
In other enGene news, CEO Ronald Harold Wilfred Cooper bought 10,000 shares of the firm's stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $5.70 per share, with a total value of $57,000.00. Following the acquisition, the chief executive officer now owns 10,000 shares of the company's stock, valued at $57,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth Opportunities F. Forbion purchased 11,844 shares of the business's stock in a transaction on Monday, October 7th. The shares were acquired at an average cost of $6.55 per share, with a total value of $77,578.20. Following the acquisition, the insider now directly owns 2,469,833 shares in the company, valued at approximately $16,177,406.15. The trade was a 0.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 420,965 shares of company stock valued at $2,651,103 in the last quarter. Company insiders own 13.70% of the company's stock.
ENGN has been the subject of a number of analyst reports. Morgan Stanley reaffirmed an "overweight" rating and set a $40.00 target price on shares of enGene in a report on Wednesday, September 11th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price objective on shares of enGene in a research note on Friday, December 6th. Oppenheimer reiterated an "outperform" rating and issued a $30.00 price objective on shares of enGene in a report on Tuesday, September 24th. Raymond James started coverage on enGene in a report on Wednesday, November 27th. They set an "outperform" rating and a $23.00 target price on the stock. Finally, Citizens Jmp raised enGene to a "strong-buy" rating in a research note on Monday, November 18th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $30.38.
Check Out Our Latest Stock Report on enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.